<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="312">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579471</url>
  </required_header>
  <id_info>
    <org_study_id>s64036</org_study_id>
    <nct_id>NCT04579471</nct_id>
  </id_info>
  <brief_title>Prevalence and Outcome of SARS-CoV-2 Infection &amp; COVID-19 in Transplant Recipients: The COVITRA Study</brief_title>
  <acronym>COVITRA</acronym>
  <official_title>Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will provide novel data using a large cohort of more than 3000 transplanted&#xD;
      patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity&#xD;
      will be identified. The proportion of patients who develop antibodies after infection will be&#xD;
      revealed. In this way the presence of these antibodies can be evaluated as a test for prior&#xD;
      infection. Our study additionally will demonstrate how long these antibodies remain present&#xD;
      and whether they are protective against a new infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence and risk-factors for SARS-CoV-2 infection</measure>
    <time_frame>inclusion during 4 months</time_frame>
    <description>Prevalence and risk-factors for SARS-CoV-2 infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence and risk-factors for COVID-19</measure>
    <time_frame>inclusion during 4 months</time_frame>
    <description>Prevalence and risk-factors for COVID-19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of IgG positivity</measure>
    <time_frame>12 months</time_frame>
    <description>Durability of IgG positivity/immunity</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Transplantation Infection</condition>
  <arm_group>
    <arm_group_label>Transplanted patients</arm_group_label>
    <description>All patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transplanted patients with past SARS-CoV-2 infection</arm_group_label>
    <description>Transplanted patients with past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transplanted patients without past SARS-CoV-2 infection</arm_group_label>
    <description>100 transplanted patients without past SARS-CoV-2 infection will be followed for one year (at month 3, 6 and 12 after the initial study visit) to assess durability of IgG positivity and as control for the transplanted patients with WITH past SARS-CoV-2 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2 IgG</intervention_name>
    <description>Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies</description>
    <arm_group_label>Transplanted patients</arm_group_label>
    <arm_group_label>Transplanted patients with past SARS-CoV-2 infection</arm_group_label>
    <arm_group_label>Transplanted patients without past SARS-CoV-2 infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection and storage plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        all patients who underwent solid organ or hematopoietic transplantation at UZ Leuven and&#xD;
        who give informed consent&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients who underwent solid organ or hematopoietic cell transplantation at UZ&#xD;
             Leuven and who give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age under 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jef Verbeek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jef Verbeek, MD, PhD</last_name>
    <phone>+ 32 16 34 42 25</phone>
    <email>jef.verbeek@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalie Van den Ende</last_name>
    <phone>+32 16 340749</phone>
    <email>natalie.vandenende@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jef Verbeek, MD</last_name>
      <phone>+32 16 345845</phone>
      <email>jef.verbeek@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Vandenende</last_name>
      <phone>+32 16 34 07 49</phone>
      <email>natalie.vandenende@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jef Verbeek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>SARS-CoV Infection</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

